This book is written by International experts in their field and should appeal to students and seasoned researchers, to scientists and to clinicians. No prior knowledge of the topic is required to appreciate this text and yet the book charters new territory. New perspectives are given on how our knowledge of cancer development might lead us to reconsider our clinical approach to early detection and prevention of cancer at an individual and population level.
This book is written by International experts in their field and should appeal to students and seasoned researchers, to scientists and to clinicians. No prior knowledge of the topic is required to appreciate this text and yet the book charters new territory. New perspectives are given on how our knowledge of cancer development might lead us to reconsider our clinical approach to early detection and prevention of cancer at an individual and population level.
Rebecca Fitzgerald is a tenured Programme Leader at the Medical Research Council (MRC) Cancer Cell Unit in Cambridge and her research is in Barrett's oesophagus with a particular focus on early cancer detection. She trained at Cambridge University, conducted her doctoral research at Stanford University, California and came to the UK for her post-doctoral research and specialist clinical training at St. Barts and the London Hospitals before returning to Cambridge. Rebecca maintains an clinical active practice as an honorary consultant in Gastroenterology at the University teaching hospital Addenbrooke's and enjoys teaching in her capacity as Director of Studies at Trinity College, Cambridge.
Inhaltsangabe
Guest editorial: Professor Sir Bruce Ponder (AGREED)
1. Epidemiology: public health burden, increasing disease and/or increasing detection, lag phase, risk factors ? Prof. John Potter Fred Hutchinson Centre/? Paul Pharoah
2. Pathogenesis:
- cancer stem cells: Prof. Sir Nick Wright, London Research Institute
- inflammation: Lisa Coussens, University California San Francisco
- hereditary factors: Paul Pharoah/Bruce Ponder CRI, Cambridge
- acquired mutations: Doug Hanahan /Robert Weinberg, University California San Francisco
- Epigenetics: E.G. William Nelson Baltimore/ Steve Meltzer John Hopkins USA
3. Animal models and other model systems of pre-invasive disease e.g. Tyler Jacks MIT or Dave Tuveson, CRI cambridge
4. Biomarkers - tissue, serum, fluids: Prof. Brian Reid, Fred Hutchinson Cancer Center, Seattle or Barbara Weber, GSK Pharmaceuticals
5. Molecular imaging: Professor Kevin Brindle Cambridge Research Institute, UK or Gary Kelloff NCI, Rockville
6. Issues around screening/surveillance: psychosocial, economic: Dr. Dawn Provenzale Duke University/ Karen Basen-Engquist MD Anderson texas/ prof Jane Blazeby Bristol UK
7. Disease specific examples:
Lung: Herman Baltimore
Mouth: Miriam Rosin Vancouver
Oesophagus: Dr Rebecca Fitzgerald, Cambridge UK
Stomach: Dr. Tim Wang, Columbia Univ, New York
Colon: Prof Bert Vogelstein, John Hopkins USA, John Potter, Seattle
Prostate/bladder: Professor David Neal, CRI Cambridge
8. Chemoprevention: e.g. Prof. John Potter Fred Hutchinson Centre
9. Treatment of early lesions: Jacques Van Dam Stanford / or Jacques Bergman Amsterdam
10. Common threads: areas for future research and future costs.benefits to society for early detection: or Michael Sporn Dartmouth Med Sch New Hampshire, or Gary Kelloff NCI, Maryland or Prof. George Triadafilopoulos, Stanford
Guest editorial: Professor Sir Bruce Ponder (AGREED)
1. Epidemiology: public health burden, increasing disease and/or increasing detection, lag phase, risk factors ? Prof. John Potter Fred Hutchinson Centre/? Paul Pharoah
2. Pathogenesis:
- cancer stem cells: Prof. Sir Nick Wright, London Research Institute
- inflammation: Lisa Coussens, University California San Francisco
- hereditary factors: Paul Pharoah/Bruce Ponder CRI, Cambridge
- acquired mutations: Doug Hanahan /Robert Weinberg, University California San Francisco
- Epigenetics: E.G. William Nelson Baltimore/ Steve Meltzer John Hopkins USA
3. Animal models and other model systems of pre-invasive disease e.g. Tyler Jacks MIT or Dave Tuveson, CRI cambridge
4. Biomarkers - tissue, serum, fluids: Prof. Brian Reid, Fred Hutchinson Cancer Center, Seattle or Barbara Weber, GSK Pharmaceuticals
5. Molecular imaging: Professor Kevin Brindle Cambridge Research Institute, UK or Gary Kelloff NCI, Rockville
6. Issues around screening/surveillance: psychosocial, economic: Dr. Dawn Provenzale Duke University/ Karen Basen-Engquist MD Anderson texas/ prof Jane Blazeby Bristol UK
7. Disease specific examples:
Lung: Herman Baltimore
Mouth: Miriam Rosin Vancouver
Oesophagus: Dr Rebecca Fitzgerald, Cambridge UK
Stomach: Dr. Tim Wang, Columbia Univ, New York
Colon: Prof Bert Vogelstein, John Hopkins USA, John Potter, Seattle
Prostate/bladder: Professor David Neal, CRI Cambridge
8. Chemoprevention: e.g. Prof. John Potter Fred Hutchinson Centre
9. Treatment of early lesions: Jacques Van Dam Stanford / or Jacques Bergman Amsterdam
10. Common threads: areas for future research and future costs.benefits to society for early detection: or Michael Sporn Dartmouth Med Sch New Hampshire, or Gary Kelloff NCI, Maryland or Prof. George Triadafilopoulos, Stanford
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
